Jul 6, 2021
Experienced Industry Leader with successful Oncology, Immunotherapy & ADC Development Track Record Adcendo, a biotech company developing innovative antibody-drug conjugates (ADCs) for the treatment of underserved cancers, announces today the appointment of Michael...
Apr 29, 2021
Adcendo raises EUR 51 Million in Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers Financing led by Novo Seeds and Ysios Capital is largest Series A for a Danish biotech companyPlans to build a pipeline of ADCs directed at novel...